<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aclaris Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc</link>
<description>Latest news and press releases for Aclaris Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aclaris-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835423978dffbe2df0e130c.webp</url>
<title>Aclaris Therapeutics Inc</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc</link>
</image>
<item>
<title>Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indicati...</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-from-phase-1a-healthy-volunteer-clinical-trial-of-ati-052-a-novel-potential-first-in-class-anti-tslpil-4ra-bispecific-antibody-and-announces-lichen-planus-as-lead-indicati</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-from-phase-1a-healthy-volunteer-clinical-trial-of-ati-052-a-novel-potential-first-in-class-anti-tslpil-4ra-bispecific-antibody-and-announces-lichen-planus-as-lead-indicati</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential</description>
</item>
<item>
<title>Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibitor-programs-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibitor-programs-on-april-28-2026</guid>
<pubDate>Mon, 27 Apr 2026 20:45:00 GMT</pubDate>
<description>WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the fin</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-participate-in-the-hc-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-participate-in-the-hc-wainwright-4th-annual-inflammatory-skin-disease-virtual-conference</guid>
<pubDate>Wed, 08 Apr 2026 12:30:00 GMT</pubDate>
<description>WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference</description>
</item>
<item>
<title>Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/results-presented-at-2026-american-academy-of-dermatology-aad-annual-meeting-provide-additional-support-for-the-therapeutic-potential-of-ati-2138</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/results-presented-at-2026-american-academy-of-dermatology-aad-annual-meeting-provide-additional-support-for-the-therapeutic-potential-of-ati-2138</guid>
<pubDate>Fri, 27 Mar 2026 14:10:00 GMT</pubDate>
<description>- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent</description>
</item>
<item>
<title>Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-poster-on-results-from-phase-2a-trial-of-ati-2138-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-poster-on-results-from-phase-2a-trial-of-ati-2138-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-completes-enrollment-in-phase-2-trial-of-bosakitug-ati-045-in-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-completes-enrollment-in-phase-2-trial-of-bosakitug-ati-045-in-atopic-dermatitis</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid</description>
</item>
<item>
<title>Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-initiates-phase-1b-proof-of-concept-trial-in-patients-with-asthma-with-its-novel-bispecific-anti-tslpil-4ra-antibody-ati-052</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-initiates-phase-1b-proof-of-concept-trial-in-patients-with-asthma-with-its-novel-bispecific-anti-tslpil-4ra-antibody-ati-052</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in Two February Healthcare Conferences</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-two-february-healthcare-conferences-2026-02-04</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-two-february-healthcare-conferences-2026-02-04</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-novel-itk-jak3-115500581</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-novel-itk-jak3-115500581</guid>
<pubDate>Tue, 27 Jan 2026 11:55:00 GMT</pubDate>
<description>- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata (AA). In this model of</description>
</item>
<item>
<title>Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-initiates-phase-1b-proof-concept-trial-atopic-dermatitis-ad-its</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-initiates-phase-1b-proof-concept-trial-atopic-dermatitis-ad-its</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-positive-interim-115900764</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-positive-interim-115900764</guid>
<pubDate>Tue, 06 Jan 2026 11:59:00 GMT</pubDate>
<description>- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - ...</description>
</item>
<item>
<title>Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-added-nasdaq-biotechnology-index-nbi-2025-12-19</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-added-nasdaq-biotechnology-index-nbi-2025-12-19</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress,</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in Three November Healthcare Conferences</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-three-november-healthcare-conferences-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-three-november-healthcare-conferences-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-host-person-and-webcast-rd-day-patient-focused-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-host-person-and-webcast-rd-day-patient-focused-innovation</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-late-breaking-abstract-and-oral-presentation-ati-2138</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-announces-late-breaking-abstract-and-oral-presentation-ati-2138</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Aclaris Therapeutics to Participate in Two September Healthcare Conferences</title>
<link>https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-two-september-healthcare-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/aclaris-therapeutics-inc/news/aclaris-therapeutics-participate-two-september-healthcare-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
</channel>
</rss>